Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Pictet Asset Management Ltd.

Pictet Asset Management Ltd. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 3,026,485 shares of the company’s stock after buying an additional 12,397 shares during the period. Pictet Asset Management Ltd. owned approximately 0.30% of Teva Pharmaceutical Industries Limited worth $84,318,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Renaissance Technologies LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock valued at $154,602,000 after buying an additional 2,651,900 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock valued at $46,065,000 after buying an additional 1,435,151 shares during the period. Sei Investments Co. raised its position in shares of Teva Pharmaceutical Industries Limited by 103.6% in the second quarter. Sei Investments Co. now owns 1,721,466 shares of the company’s stock valued at $57,188,000 after buying an additional 875,789 shares during the period. Ameriprise Financial Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 142.2% in the first quarter. Ameriprise Financial Inc. now owns 1,288,571 shares of the company’s stock valued at $41,349,000 after buying an additional 756,441 shares during the period. Finally, Commerzbank Aktiengesellschaft FI raised its position in shares of Teva Pharmaceutical Industries Limited by 370.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 929,084 shares of the company’s stock valued at $29,814,000 after buying an additional 731,666 shares during the period. 56.27% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 18.59 on Tuesday. The company has a market capitalization of $18.89 billion, a P/E ratio of 238.33 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 1-year low of $18.50 and a 1-year high of $55.45. The company has a 50-day moving average of $32.05 and a 200-day moving average of $32.28.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period last year, the firm earned $1.25 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.83%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -18.95%.

ILLEGAL ACTIVITY WARNING: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.themarketsdaily.com/2017/08/08/teva-pharmaceutical-industries-limited-nyseteva-shares-bought-by-pictet-asset-management-ltd.html.

Several research analysts recently issued reports on the stock. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price for the company. in a research report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Barclays PLC cut their target price on shares of Teva Pharmaceutical Industries Limited from $38.00 to $23.00 and set an “equal weight” rating for the company in a research report on Monday. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Finally, Maxim Group reiterated a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. One analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $39.19.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply